Tema Oncology ETF (CANC)
NASDAQ (NMS) NASDAQ (NMS) Primary Summary
CANC Chart
CANC: I Give A Hold Rating To This ETF That Invests In Cancer-Fighting Stocks
Tema Oncology ETF receives a Hold rating due to inconsistent returns but it does currently have a high Quant Ranking in the healthcare subclass. CANC offers diversified exposure across market caps and geographies, focusing on firms combating cancer through biotech, pharmaceuticals, diagnostics, and devices. The ETF holds 55 stocks, with top 10 comprising 40% of the portfolio, balancing established giants and innovative small-caps.
Disruptive Theme of the Week – Breakthroughs in Medicine
Medical breakthroughs are occurring constantly, but they often get lost in the news headlines unless they directly impact our lives. I wanted to take a moment to highlight a few recent medical breakthroughs and developments and explore a few ways to get actionable exposure to them with ETFs.
Tema Oncology ETF Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Heather LeVar Roxbury Financial LLC | 3,940 | $148,875.92 | $162,882.75 | $14,006.83 | 9.41% |
Tema Oncology ETF (CANC) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Tema Oncology ETF ever had a stock split?
Tema Oncology ETF Profile
| NASDAQ (NMS) Exchange | US Country |
Overview
The described fund is an investment entity that primarily focuses on allocating its resources into publicly listed companies which are significantly involved in the oncology sector. By setting a threshold of investing at least 80% of its net assets—this includes leveraging with borrowings for the purpose of investment—in such companies, the fund demonstrates a strong commitment to supporting and being part of the growth within the oncology field. These companies must derive a minimum of 50% of their revenues from oncology-related activities, ensuring that the fund's investments are deeply entrenched within the cancer treatment and research sector. Operating as a non-diversified fund, it indicates a targeted approach to investment, concentrating its assets in a relatively narrow market segment, which in this case, focuses on oncology and its associated industries.
Products and Services
- Investment in Oncology-Focused Companies
This service involves identifying and investing in publicly listed companies that are heavily engaged in the oncology sector. By ensuring that at least 50% of these companies' revenues come from oncology-related activities, the fund dedicates a significant portion of its portfolio to support the growth and innovation within the field of cancer research and treatment. This strategic focus not only aims at generating returns for the investors but also contributes to the broader goal of advancing oncology therapeutics and technologies.
- Leveraged Investment for Enhanced Exposure
The fund employs a strategy of leveraging, which involves borrowing for the purpose of investment to augment the capital available for allocation in its chosen market. This approach allows the fund to enhance its exposure to the oncology sector, potentially increasing the scale of its investments and the corresponding impact. While leveraging can introduce a higher level of risk due to the possibility of increased losses, it also opens up opportunities for significant gains, particularly in a high-growth sector like oncology.
